FR13C0009I1 - - Google Patents

Info

Publication number
FR13C0009I1
FR13C0009I1 FR13C0009C FR13C0009I1 FR 13C0009 I1 FR13C0009 I1 FR 13C0009I1 FR 13C0009 C FR13C0009 C FR 13C0009C FR 13C0009 I1 FR13C0009 I1 FR 13C0009I1
Authority
FR
France
Prior art keywords
peptide
absent
formula
satiety
appetite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0009(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR13C0009I1 publication Critical patent/FR13C0009I1/fr
Application granted granted Critical
Publication of FR13C0009I2 publication Critical patent/FR13C0009I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR13C0009C 1996-03-01 2013-02-12 Peptide de suppression de l'appetit, ses compositions et son utilisation Active FR13C0009I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK23196 1996-03-01
DK23096 1996-03-01
EP01122701A EP1231218B1 (en) 1996-03-01 1997-02-27 An appetite-suppressing peptide, its compositions and use
EP97905000A EP0891378B1 (en) 1996-03-01 1997-02-27 Use of a pharmaceutical composition comprising an appetite-suppressing peptide

Publications (2)

Publication Number Publication Date
FR13C0009I1 true FR13C0009I1 (el) 2013-03-22
FR13C0009I2 FR13C0009I2 (fr) 2013-08-16

Family

ID=26063575

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0009C Active FR13C0009I2 (fr) 1996-03-01 2013-02-12 Peptide de suppression de l'appetit, ses compositions et son utilisation

Country Status (22)

Country Link
EP (4) EP1231218B1 (el)
JP (1) JP4064460B2 (el)
KR (1) KR100611130B1 (el)
CN (1) CN1112367C (el)
AT (3) ATE227737T1 (el)
AU (1) AU710818B2 (el)
BR (1) BR9707807A (el)
CA (1) CA2246733C (el)
CY (2) CY2619B2 (el)
CZ (1) CZ297338B6 (el)
DE (3) DE69740176D1 (el)
DK (2) DK0891378T3 (el)
ES (3) ES2364705T3 (el)
FR (1) FR13C0009I2 (el)
HU (1) HU229234B1 (el)
IL (1) IL125805A0 (el)
NO (2) NO323043B1 (el)
PL (1) PL187095B1 (el)
PT (1) PT1975177E (el)
RU (1) RU2197261C2 (el)
UA (1) UA70283C2 (el)
WO (1) WO1997031943A1 (el)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
EP1231218B1 (en) * 1996-03-01 2008-05-14 Novo Nordisk A/S An appetite-suppressing peptide, its compositions and use
ATE227309T1 (de) 1996-04-12 2002-11-15 Ontario Inc 1149336 Analoge des glucagon ähnlichen peptides -2
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU4863797A (en) * 1996-11-12 1998-06-03 Novo Nordisk A/S Use of glp-1 peptides
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
WO1999014239A1 (de) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Zusammensetzung zur therapie von diabetes mellitus und fettsucht
JP2001525371A (ja) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
EP1062240B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002504527A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
WO1999047161A1 (en) * 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
AU2002213925A1 (en) 2000-09-18 2002-03-26 Osteometer Biotech As Use of glp-1 and flp-2 peptides for treatment of bone disorders
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
AU2002224124A1 (en) 2000-12-01 2002-06-11 Takeda Chemical Industries Ltd. Method for producing preparation containing bioactive substance
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
ATE502665T1 (de) 2003-02-04 2011-04-15 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
EP1694356B1 (en) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
EP2368579A1 (en) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
ATE531374T1 (de) * 2004-04-15 2011-11-15 Alkermes Inc Vorrichtung auf polymerbasis mit verzögerter freisetzung
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
WO2005120492A1 (en) 2004-06-11 2005-12-22 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101200227B1 (ko) 2005-05-04 2012-11-13 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
PL1767545T3 (pl) 2005-09-22 2010-04-30 Biocompatibles Uk Ltd Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
NZ576260A (en) 2006-11-08 2012-04-27 Zealand Pharma As GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
WO2009021293A1 (en) * 2007-08-16 2009-02-19 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2872315A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
BR112019010624A2 (pt) 2016-12-09 2019-10-22 Zealand Pharma As agonistas duplos de glp-1/glp-2 acilados e composição
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
WO2020223761A1 (en) * 2019-05-06 2020-11-12 The University Of Sydney Methods for the fractionation of proteins

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
JPS60501140A (ja) 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
AU6543286A (en) 1985-10-25 1987-05-19 Zymogenetics Inc. Method of using bar1 for secreting foreign proteins
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
ATE170557T1 (de) 1987-07-24 1998-09-15 Chiron Corp Züchtung von insektenzellen mit airlift-reaktoren
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
AU4647889A (en) 1988-11-18 1990-06-12 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP1231218B1 (en) * 1996-03-01 2008-05-14 Novo Nordisk A/S An appetite-suppressing peptide, its compositions and use

Also Published As

Publication number Publication date
JP4064460B2 (ja) 2008-03-19
CA2246733A1 (en) 1997-09-04
PL328732A1 (en) 1999-02-15
CZ273698A3 (cs) 1998-12-16
NO984005L (no) 1998-08-31
HU229234B1 (en) 2013-09-30
NO984005D0 (no) 1998-08-31
FR13C0009I2 (fr) 2013-08-16
EP0891378B1 (en) 2002-11-13
ATE227737T1 (de) 2002-11-15
ES2364705T3 (es) 2011-09-12
ES2187756T3 (es) 2003-06-16
UA70283C2 (en) 2004-10-15
PL187095B1 (pl) 2004-05-31
NO323043B1 (no) 2006-12-27
ATE395359T1 (de) 2008-05-15
DE69717092T2 (de) 2003-07-24
EP1975177A1 (en) 2008-10-01
DE69738695D1 (de) 2008-06-26
AU1871597A (en) 1997-09-16
CZ297338B6 (cs) 2006-11-15
CY2013008I2 (el) 2015-08-05
ES2306685T3 (es) 2008-11-16
IL125805A0 (en) 1999-04-11
BR9707807A (pt) 1999-07-27
EP1231218A2 (en) 2002-08-14
JP2000505460A (ja) 2000-05-09
DK0891378T3 (da) 2003-01-06
CY2619B2 (el) 2013-03-13
NO2013006I1 (no) 2013-04-02
AU710818B2 (en) 1999-09-30
RU2197261C2 (ru) 2003-01-27
EP1975177B1 (en) 2011-04-13
CA2246733C (en) 2010-07-20
PT1975177E (pt) 2011-07-26
EP0891378A1 (en) 1999-01-20
KR100611130B1 (ko) 2006-11-30
CN1215405A (zh) 1999-04-28
ATE505485T1 (de) 2011-04-15
EP1231218A3 (en) 2002-10-30
HUP9902670A3 (en) 2000-02-28
CN1112367C (zh) 2003-06-25
EP2295453A3 (en) 2011-03-30
DE69740176D1 (de) 2011-05-26
NO2013006I2 (el) 2013-03-12
DE69717092D1 (de) 2002-12-19
CY2013008I1 (el) 2015-08-05
DK1975177T3 (da) 2011-07-25
EP2295453A2 (en) 2011-03-16
KR19990087439A (ko) 1999-12-27
EP1231218B1 (en) 2008-05-14
WO1997031943A1 (en) 1997-09-04

Similar Documents

Publication Publication Date Title
NO2013006I2 (el)
EP1529534A3 (en) Use of GLP-1 peptides
PL343104A1 (en) Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
NO992557L (no) Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme
EP0906310A4 (en) OXADIAZOLE-BENZOSULFONAMIDES AS SELECTIVE BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETIS AND OBESITY
DK1171465T3 (da) Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
GB9614191D0 (en) Oxadiazole benzenesulfonamides as selectives B3 agonists for the treatment of diabetes and obesity
ATE305478T1 (de) Topoisomerase-ii inhibitoren
MX9601655A (es) Proteinas (ob) obesas recombinantes.
ATE303438T1 (de) Menschlicher cysteinyl leukotrien rezeptor 2 (cyslt2)
PL334317A1 (en) Application of peripherally administered glp-1 analoques and derivatives in treating obesity